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Background: Endocardiosis is the most common heart disease in Dachshunds and is therefore an important cause
of cardiac morbidity and death. In recent years we have observed an increasing interest in the development of new
genetic and genomic markers of heart disease. The discovery of miRNAs circulating in biofluids such as plasma or
serum aroused researchers’ interest in using them as potential biomarkers. In the present study we analysed the
expression of 9 miRNAs described in literature as being involved in cardiovascular pathology in the plasma of dogs
suffering from endocardiosis.
Results: Expression analysis using the Real-time PCR method revealed that two out of nine miRNAs were significantly
downregulated: the expression of miR-30b differed between ACVIM stage B and stage A (control) dogs; the expression
of mi-133b differed ACVIM stage C and stage A dogs. 5 miRNAs (miR-125, miR-126, miR-21, miR-29b and miR-30b)
showed a trend of downregulation in the ACVIM C group. Levels of miR-423 were the same in healthy and diseased
dogs. Expression of miR-208a and 208b was not detected.
Conclusions: miR-30b could be a potential biomarker of ACVIM stage B heart failure in Dachshunds with endocardiosis
and miR-133b could be a potential biomarker of ACVIM stage C. The lack of expression or lack of significant changes in
expression in 7 miRNAs which are potential biomarkers of heart diseases in humans proves that findings from human
medicine are not always directly reflected in veterinary medicine.
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Endocardiosis is the most common heart disease in
Dachshunds and is therefore an important cause of car-
diac morbidity and death. It is recognised mainly in
middle-aged and older dogs. It is also referred to as myx-
omatous atrioventricular valvular degeneration, chronic
degenerative valvular heart disease (CVHD), or chronic
valvular fibrosis. Endocardiosis is characterised by pro-
gressive lesions affecting primarily the mitral valve, and
less frequently the tricuspid valve. Affected valve leaflets
are grossly shortened and thickened and have nodular
areas along the free valvular edges. During disease pro-
gress, lesions extend and occupy larger areas of the valve
surface, sometimes encompassing the chordae tendineae.* Correspondence: magda.hulanicka@gmail.com
1Department of Physiological Sciences, Faculty of Veterinary Medicine,
Warsaw University of Life Sciences, Nowoursynowska str. 159c, 02-776
Warsaw, Poland
Full list of author information is available at the end of the article
© 2014 Hulanicka et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.In most cases atrioventricular valvulopathy occurs in the
dog spontaneously and is age-related [1-3].
In recent years significant development of new diagnos-
tic methods allowing precise diagnosis of animal diseases
as well as better understanding of their background has
been observed. Genetics is a very important aspect of dog
breeding and reproduction, and another significant reason
why we have been observing a great interest in the devel-
opment of new genetic and genomic markers of specific
diseases. One group of such markers could be miRNA.
miRNAs inhibit gene expression at the post-
transcriptional level by directing the RISC complex to
target mRNAs resulting in translational repression or
cleavage [4]. The transcription profile of many genes
can be influenced by miRNAs. This is why they have
emerged as crucial regulators of a wide range of physio-
logical and pathological processes.
Several studies have recently discovered circulating miR-
NAs in blood, not only in platelets, nucleated blood cells,
and erythrocytes, but also in plasma. Moreover, plasmaral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conditions such as boiling, long time storage at room
temperature and low or high pH, whereas exogenously
added synthetic miRNAs are quickly degraded because of
RNAse activity in the plasma [5-7]. This means that en-
dogenous miRNAs present in plasma must be shielded in
some way from degradation. Recent studies have showed
that miRNAs are packaged in lipid vesicles (exosomes,
microvesicles, apoptotic bodies) or associated with RNA-
binding proteins or lipoprotein complexes [8-12]. These
properties make miRNAs ideal stable novel diagnostics
biomarkers, which can be measured in easy accessible
samples and can be used to diagnose different pathological
conditions. Plasma and serum miRNAs are currently be-
ing intensively investigated and specific miRNA expression
patterns are being reported for various pathological condi-
tions in humans. The results of recent studies show that
circulating miRNAs are potential biomarkers for detection
of cancer [13-16] and heart disease [17-19].
However, in veterinary medicine the situation is quite
different–there are only few reports about research on cir-
culating miRNAs research in animal diseases. To our best
knowledge there is only one report concerning circulating
miRNA levels in dogs with heart disease. This study com-
pares expression of miRNAs in the serum of Doberman
Pinschers with dilated cardiomyopathy (DCM) in com-
parison to healthy control dogs.
Therefore the aim of the present paper was to com-
pare levels of miRNAs in the plasma of Dachshunds
with endocardiosis and healthy control dogs. Moreover,
dogs with endocardiosis were divided in two groups ac-
cording to the ACVIM (American College of Veterinary
Internal Medicine) classification scheme [20]. The results
of our previous study revealed that the biggest differences
in expression of genes in peripheral blood nuclear cells
were observed when healthy dogs and ACVIM stage C
(mild to moderate heart failure) dogs where compared, so
we decided to include the ACVIM stage C group in the
present study. Furthermore, we also included the ACVIM
stage B group in our study, which is a group of great im-
portance since this is the asymptomatic stage of the dis-
ease and deemed to be important for early diagnostics.
The potential identification of any prognostic marker of
canine endocardiosis would be very important for the sta-
ging of disease progress, therapy assessment as well as for
breeding purposes. It could give new insight into the
pathogenesis and staging of the disease which could help
in the effective planning of treatment.
Results
Patient characteristics
24 client-owned Dachshunds were examined cardiologi-
cally in the Cardiology Service of the Small Animal Clinic,
Faculty of Veterinary Medicine, School of Agriculture inWarsaw. Dogs included in the study were assigned to
ACVIM B (n = 8), ACVIM C (n = 8) or ACVIM A–un-
affected control group (n = 8) according to the ACVIM
(American College of Veterinary Internal Medicine) classi-
fication scheme. One sample of the ACVIM C group was
removed from further analysis because of inconsistency of
expression levels of miRNA compared to other samples.
Study population characteristics are shown in Table 1.
qPCR
Nine miRNAs which have been previously described in lit-
erature as being involved in cardiovascular pathology in
humans were selected for qPCR analysis (Table 2). The ex-
pression of each miRNA in the plasma of dogs was com-
pared between the ACVIM stage B group and unaffected
dogs (ACVIM stage A) using parametric t-test and Bonfer-
roni correction. The results revealed that miR-30b was sig-
nificantly downregulated in ACVIM stage B–its expression
was -2.63 times lower than in unaffected dogs. The rest of
analysed miRNAs showed almost no differences between
these two groups. Moreover, results showed a high interin-
dividual variance of expression. miR-208a and miR-208b
were not detected in any of the examined samples
(in both healthy group of dogs–ACVIM stage A and
ACVIM stage B) (Figure 1).
Using the same statistical tests the expression of miRNAs
in ACVIM stage C and unaffected dogs was analysed. We
observed a trend of downregulation in all examined miR-
NAs. The biggest differences were observed in case of miR-
133b. The expression of this miRNA was -3.29 times lower
in ACVIM stage C than in unaffected dogs. miR-29b and
miR-423 remained almost unchanged but the other
miRNAs were slightly downregulated. The mean fold
change for each of them was as follows: -1.84 for miR-30b,
-1.55 for miR-126, -1.82 for miR-125. Likewise in ACVIM
stage B class the expression of miR-208a and miR-208b
were not detected (Figure 2).
Discussion
This study reports the results of an evaluation of the ex-
pression of miRNAs as potential biomarkers in the
plasma of dogs suffering from endocardiosis. Endocar-
diosis (also referred to as chronic degenerative valvular
disease or myxomatous valve disease) can lead to con-
gestive heart failure and the associated clinical signs.
Since the molecular background of this disease is still far
from fully elucidated, the search for any specific markers
(prognostic, therapeutic) of this disease would be of
great value and importance.
Although miRNA are currently intensively investigated
in human medicine because of their diagnostic potential
in many different conditions, there are only few reports
related to circulating miRNA studies in animal diseases.
One of these is the study about expression of miRNAs
Table 1 Clinical characteristics of the study population in the control, ACVIM B and ACVIM C groups
ACVIM stage ACVIM A–unaffected (mean ± SD) ACVIM B (mean ± SD) ACVIM C (mean ± SD)
Numer of dogs 8 8 7
Age range (years) 5.458 ± 2.51 10.17 ± 3.36 10.40 ± 4.73
Sex Males 2 4 5
Females 6 4 3
Body weight (kg) 10.38 ± 3.26 9.46 ± 2.13 9.20 ± 1.83
EF % 71.25 ± 12.26 69.5 ± 8.21 77.14 ± 3.39
LA/Ao 1.223 ± 0.10 1.479 ± 0.41 1.774 ± 0.21*
LA cm 1.938 ± 0.47 2.348 ± 0.54 2.811 ± 0.32*
LVDd 2.863 ± 0.24 2.993 ± 0.43 3.529 ± 0.42**
MVR 0 5.466 ± 1.05*** (n = 5) 5.963 ± 0.78***
RVDd 0.9375 ± 0.17 0.9275 ± 0.14 0.6057 ± 0.21**
TVR m/s 0.3988 ± 1.13 0.925 ± 1.39 2.379 ± 1.19*
*statistically significant difference vs healthy dogs with p < 0.05; **statistically significant difference vs healthy dogs with p < 0.01; ***statistically significant
difference vs healthy dogs with p < 0.001.
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opathy (DCM). The authors compared the expression of
1368 miRNAs using miRNA microarrays. They identified
404 different miRNAs but the results did not show statis-
tical significance after multiple testing correction (FDR)
and Real-time PCR validation of 5 miRNAs which were
differentially regulated without FDR correction showed no
statistical differences [29]. Another study conducted by
Mizuno et al. revealed that the level of muscle-specific
miRNAs are inceresed in serum of canine X-linked mus-
cular dystrophy in Japan dog model (CXMDJ) in compari-
son to wild type control dogs [30]. Moreover, there were
miRNAs quantitated in peripheral blood from dogs with
chronic lymphocytic leukemia. The results revealed dis-
tinct miRNA patterns in chronic lymphocytic leukemia
depending on the immunophenotype [31]. The number of
studies is not sufficient and much more data are neededTable 2 Overview of miRNAs in various cardiovascular disease
microRNA Disease Material
miR-30 Chronic Systolic Heart Failure Serum
miR-21 Dilated Cardiomyopathy Heart tissue
miR-29 Acute Myocardial Infarction Heart tissue
miR-126 Congestive Heart Failure Plasma
Coronary Artery Disease Plasma
Dilated Cardiomyopathy Heart tissue
miR-125 Ischemic Dilated Cardiomyopathy Peripheral blood m
miR-423 Heart Failure Plasma
Heart Failure Serum
miR-208 Acute Myocardial Infarction Plasma
Myocardial Injury Plasma
miR-133 Myocardial Infarction Heart tissueto determine whether miRNAs can be used as biomarkers
in veterinary medicine.
One of the difficulties researchers face related to circu-
lating miRNA studies is the impossibility of reliable large–
scale expression screening using the microarray method.
Microarray analysis is not a suitable method for studying
miRNAs expression in biofluids because of insufficient
sensitivity which cannot ensure reproducible detection of
samples with low miRNA levels [18]. The results of a
study conducted by Jensen et al. revealed that the best spe-
cificity, sensitivity reproducibility, recovery and linearity in
circulating miRNA studies is attained with the Real-time
PCR method, which is based on Locked Nucleic Acid
(LNA™) technology [32]. This is why we decided to apply
this method in our analysis.
Our study included 24 client-owned dogs with endo-














Figure 1 The expression of 9 miRNAs in dogs with ACVIM stage
B of heart failure in comparison to unaffected control (fold
changes relative to healthy group; mean ± SEM).
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sification scheme. The results revealed that among nine
miRNAs that have been previously connected to heart
disease in literature (Table 2), there were two miRNAs
significantly downregulated in plasma of Dachshunds
with progression of endocardiosis. miR-30b was down-
regulated in ACVIM stage B dogs when compared to
ACVIM stage A dogs (this miRNA also showed a down-
regulatory trend in ACVIM stage C dogs) and miR-133b
was downregulated in ACVIM stage C dogs. These miR-
NAs could be potential diagnostic biomarkers of en-
docardiosis in Dachshunds. miR-30 and miR-133 are
cardiomyocyte-enriched miRNAs which regulate con-
nective tissue growth factor (CTGF)–a key molecule in
the process of fibrosis and therefore an attractive thera-
peutic target of heart diseases. A decreased expression
of these two miRNAs in human pathological left ven-
tricular hypertrophy and rodent models of heart disease
allow for the increase of CTGF levels, which contributes
to collagen synthesis [33]. Downregulation of miR-30 is
related to endoplasmic reticulum stress in cardiac
muscle and vascular smooth muscle cells [34]. On theFigure 2 The expression of 9 miRNAs in dogs with ACVIM stage
C of heart failure in comparison to unaffected control (fold
changes relative to normal group; mean ± SEM).other hand the results of the study conducted by Goren
et al. revealed elevated levels of miR-30 in the serum of
stable chronic systolic heart failure patients [21]. The
second miRNA with decreased levels in our study–miR-
133 was also downregulated in human infarcted heart
tissue [28]. Another study showed that the level of miR-
133 in the plasma of patients with acute coronary syn-
drome was associated with high-sensitivity troponin T
levels [35].
The next four analyzed miRNAs–miR-21, miR-29b,
miR-125, miR-126 showed a trend of downregulation in
the mild to moderate heart failure group–ACVIM B but
the results did not reach statistical significance. The litera-
ture data for these miRNAs are present in Table 2. It is
worthwhile to mention that during the study conducted
on dogs by Steudeman et al. miR-21 was one of the 22
miRNAs that showed changed expression in the serum of
Doberman Pinchers with Dilated Cardiomyopathy–a 1.67
fold change in microarray (without false discovery rate
control), but the results of qPCR validation showed no dif-
ference between healthy and DCM dogs [29].
Although miR-208a and 208b are proposed as potential
biomarkers of heart disease in humans [17,28,35] their
expression has not been detected in any of the samples
analyzed in our study. The reason might be that the etio-
pathogenesis of the most frequent heart disease in dogs-
myxomatous valve disease may be different compared to
humans [36]. Furthermore, an analysis of the heart tran-
scriptomic profile showed a higher similarity between dog
and mouse than between dog and human [37].
Moreover, levels of miR-423, which were elevated dur-
ing left ventricular heart failure in humans [21,26], were
equal in the healthy and diseased groups of dogs in our
study. The results of the study conducted by Turatel
et al. revealed that circulating miR-423_5p was not a
useful biomarker for heart failure patients with a sys-
temic right ventricle [38]. This means that we cannot
consider miRNAs identified in one kind of heart disease
as potential biomarkers of other heart diseases. miRNA
patterns differed not only between species but showed
different expressions of the same circulating miRNA
within the same species and disease but different patient
characteristics.
An important aspect of the study is a significant age
difference between dogs belonging to different experi-
mental groups. This is a natural phenomenon because
the more advanced heart disease is always related to
older age. The question is whether the age differences
between experimental groups influence the findings of
this study. This could be quite an important question
since it is known that miRNAs may play a role in the
age-related changes in the skeletal muscle phenotype
[39]. In order to verify the presence of the age effect we
decided to correlate the expression of miRNAs not only
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the dogs. We created three groups consisting of the youn-
gest, the oldest and middle age dogs. The results of this
analysis (Additional file 1) did not show any significant
changes in expression of miRNAs between these three dif-
ferent age groups. Thus we concluded that the cause of the
changed expression of miR-30b and miR-133b in our study
was the stage of the disease, not the age of the animals.
The utility of circulating miRNAs as biomarkers of
many diseases has attracted considerable attention over
recent years. However, it is also worthwhile to point out
that the clinical application of miRNAs as biomarkers is
still limited. One of the most significant obstacles is the
difficulty concerning circulating miRNA normalization.
Spiked in synthetic miRNA are widely used to normalize
serum and plasma miRNA expression, but this approach
does not include effects of pre-analytic variables on cir-
culating miRNA measurement [40,41]. That is why we
decided to use a previously described housekeeping gene
in our study–miR-16-5p [42,43]. This miRNA is also a
reference gene found on the Exiqon miRNome panels
for plasma and is used as a control for hemolysis. Since
the difficulties associated with hemolysis and platelet
contamination of plasma samples are also significant,
strategies were proposed to minimize the degree of red
blood cell derived miRNA contamination, as well as
minimize platelet contamination of plasma samples [44].
It must also be pointed out that the sole presence of spe-
cific miRNAs is considered to be a biomarker of disease,
infection or inflammation. There are no measuring units,
there are no possibilities of disease grading based on
miRNA concentration and there are no reference levels of
specific miRNAs in specific tissues, both healthy and dis-
eased. Despite all these deficiencies, miRNAs are still very
promising tools in the process of disease diagnostics.
Conclusions
miR-30b could be a potential biomarker of ACVIM stage
B heart failure in Dachshunds and miR-133b could be a
potential biomarker of ACVIM stage C. The lack of ex-
pression of miR-208a and 208b in healthy dogs and dogs
with heart disease and lack of significant changes in ex-
pression in the remaining 5 miRNAs which are potential
biomarkers of heart diseases in humans proves that the
findings in human medicine are not always directly
reflected in veterinary medicine.
Methods
Study population
A prospective analysis and studies were carried out on
24 dogs submitted to the Cardiology Service of the Small
Animal Clinic, Faculty of Veterinary Medicine, School
of Agriculture in Warsaw. This study complies with na-
tional and institutional guidelines on the use of animalsin clinical research according to the Polish legal act con-
cerning experiments performed on animals of January
21st, 2005 (Ustawa o doświadczeniach na zwierzętach z
dnia 21 stycznia 2005 r. (Dz. U. z 2005 r. Nr 33, poz.
289 z późn.zm.)). Since the blood for miRNAs analyses
was taken during a routine veterinary examination and
in accordance with the above mentioned legal act, a
written ethical approval from the Local Ethical Commit-
tee before beginning the study was not necessary. How-
ever, before enrolling a dog into the study, an informed
written consent for a full physical examination as well as
additional diagnostic imaging tests and blood sampling
via venepuncture was obtained from the owner and a
high standard of care was adhered to throughout each
examination. Study population characteristics are shown
in Table 1 and blood test results in Table 3. Blood test
results were not used as an exclusion criterion for this
study. The majority of blood values were within refer-
ence ranges for the University laboratory or, where ap-
plicable, within published reference ranges. The values
outside the reference ranges were minimal and the dogs
were clinically healthy showing no signs of disease during
the study, and so these values were deemed acceptable by
the authors. Statistical analyses of clinical parameters were
performed using GraphPad Prism version 5.00 (GraphPad
Software, Inc., USA).
Clinical and laboratory examinations
24 client-owned dogs were examined cardiologically dur-
ing routine veterinary examinations. The clinical picture of
the animals included: animal history, clinical examination
and echocardiographic examination. Dogs with recognized
heart disease were classified according the ACVIM
(American College of Veterinary Internal Medicine) classi-
fication scheme as stage B (asymptomatic)–8 dogs, stage C
(mild to moderate heart failure)–8 dogs and stage A–8
dogs (the control group of unaffected dogs).
A complete physical examination was performed, with a
specific emphasis on thoracic auscultation. A standard
transthoracic echocardiographic (TTE) examination was
performed in all dogs with the Aloka 4000 ultrasound
machine, equipped with a cardiology program and 2.5–7-
megahertz (mHz) sector transducers according to previ-
ously published norms. All examinations were performed
at rest without pharmacological restraint. Blood samples
for basic morphologic and biochemical analysis as well as
the transcription profile analysis were collected from the
jugular or cephalic vein. The following laboratory tests
were performed in all of the dogs: complete blood count,
serum sodium, potassium, calcium, urea, creatinine, albu-
min, liver enzymes, and cholesterol. The dogs were classi-
fied into groups based on clinical signs of heart disease
and the results of clinical examination. Echocardiography
exam was used to diagnose endocardiosis.
Table 3 Blood test results of the study population in the control, ACVIM B and ACVIM C groups
ACVIM stage ACVIM A–unaffected (mean ± SD) ACVIM B (mean ± SD) ACVIM C (mean ± SD) Reference range
PLT 272.5 ± 58.46 371.8 ± 95.81 472 ± 126.9** 200–600
Creatinine (mg/dl) 1.039 ± 0.14 0.9625 ± 0.13 0.92 ± 0.09 0.5–1.7
WBC (+10^9/l) 7.568 ± 2.21 6.498 ± 1.28 10.98 ± 3.92 5–17
RBC (+10^12/l) 7.4 ± 0.45 7.168 ± 0.47 7.559 ± 0.81 5.5–8.5
HGB (g/dl) 16.71 ± 1.13 16.11 ± 1.20 17.19 ± 1.95 12–19
HCT % 48.85 ± 3.12 48.02 ± 3.30 51.05 ± 5.91 37–57
MCV (fl) 66 ± 2.78 66.75 ± 3.20 67.43 ± 2.76 60–77
MCH (pg) 22.6 ± 0.89 22.46 ± 0.84 22.74 ± 0.63 19.5–24.5
MCHC (g/dl) 34.2 ± 0.72 33.54 ± 0.68 33.71 ± 0.91 30.8–35.9
RDW % 15.2 ± 0.58 15.36 ± 0.59 15.93 ± 0.61 13.4–18.1
Segmented neutrophils % 60.63 ± 5.63 70.63 ± 7.41 69.14 ± 7.08 51–85
Band neutrophil % 1 ± 1.60 2.88 ± 2.9 3.429 ± 3.64 0–3
Eosinophils % 7.375 ± 2.13 3.875 ± 3.27 6.857 ± 3.13 0–10
Lymphocytes % 28.5 ± 6.30 21.75 ± 7.40 17.86 ± 6.91* 8–35
Monocytes % 2.13 ± 1.25 0.63 ± 0.74 2.71 ± 1.89 0–10
Basophils % 0.375 ± 0.74 0.125 ± 0.35 0 ± 0 0–2
AsPAT (U/l) 30.93 ± 3.82 30.53 ± 5.72 35 ± 24.32 13–81
Urea (mg/dl) 28.13 ± 6.67 31.95 ± 6.46 27.97 ± 8.62 8–45
Total protein (g/l) 55 ± 3.51 55.13 ± 4.05 58.71 ± 2.69 50–83
Cholesterol (mg/dl) 207.1 ± 55.43 261.7 ± 39.9 267.7 ± 76.69 127.7–360
Ca (mg/dl) 9.638 ± 0.32 9.763 ± 0.56 9.829 ± 0.58 9.0–12.0
K (mmol/l) 4.639 ± 0.40 4.676 ± 0.39 4.854 ± 0.48 4.1–5.6
Na (mmol/l) 147.2 ± 2.43 150.2 ± 2.55* 148.9 ± 1.23 139.1–156.5
Cl (mmol/l) 111.3 ± 2.258 112.3 ± 2.872 106.5 ± 2.867** 98.7–118
HDL (mg/dl) 158.7 ± 30.05 183 ± 21.71 179.3 ± 28.75 205.3–111.0
*statistically significant difference vs healthy dogs with p < 0.05; **statistically significant difference vs healthy dogs with p < 0.01; ***statistically significant
difference vs healthy dogs with p < 0.001.
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Blood samples were collected in EDTA-K3 probes (Eqimed,
Poland). Within 2 hours the samples were centrifuged at
1300 RCF for 10 minutes at room temperature. After-
wards the 250 μl plasma aquilots were transferred toTable 4 The sequences of miRNAs and accession numbers of
Primer Tar
hsa-miR-126-5p LNA™ PCR primer set, UniRT CAU
hsa-miR-208a LNA™ PCR primer set, UniRT AUA
hsa-miR-208b LNA™ PCR primer set, UniRT AUA
hsa-miR-423-5p LNA™ PCR primer set, UniRT UGA
hsa-miR-133b LNA™ PCR primer set, UniRT UUU
hsa-miR-125b-5p LNA™ PCR primer set, UniRT UCC
hsa-miR-30b-5p LNA™ PCR primer set, UniRT UGU
hsa-miR-21-5p LNA™ PCR primer set, UniRT UUC
hsa-miR-16-5p LNA™ PCR primer set, UniRT UAG
hsa-miR-29b-3p LNA™ PCR primer set, UniRT UAG1.5 ml tubes (Eppendorf, Germany) and stored at–80°C
until RNA isolation. Before extraction plasma samples
were thawed on ice and centrifuged at 3000 × g for 5 min
at a room temperature to pellet any debris and insoluble
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total RNA including small RNAs, were purified according
to the protocol supplied with miRCURY™ RNA Isolation
Kit–Biofluids (Exiqon, Denmark). In brief this procedures
involves lyses of membranized particles using the provided
Lysis Solution, precipitation of proteins and on column re-
moving of any remaining impurities with provided Wash
Solution. During isolation RNA Spike-in template mixture
from miRCURY LNA™ Universal RT microRNA PCR,
RNA Spike-in kit (Exiqon, Denmark) and carrier-RNA
MS2 bacteriophage RNA (Roche Applied Science) were
added as recommended by the manufacturer. RNA Spike-
in kit was used for quality control of the RNA isolation
and cDNA synthesis while MS2 RNA was used to
minimize the loss of small RNA during isolation and the
technical variation between replicates in further analyses.
Total RNA was eluted by adding 50 μl of RNase-free
water. The eluted RNA was stored at–80°C until further
analysis.
cDNA synthesis and real-time RT-PCR
cDNA was synthesized using the miRCURY LNA™ Uni-
versal RT cDNA Synthesis Kit II (Exiqon, Denmark). For
quality control of this process UniSp6 Spike-in was used.
The cDNA was stored up to 5 weeks in -20°C. Directly be-
fore preparation of Real-time PCR reaction the cDNA
products were subsequently diluted 40×. All analyses were
performed on individual samples using a SYBR® Green
master mix, Universal RT (Exiqon, Denmark) as follows:
polymerase activation at 95°C for 10 minutes; amplifi-
cation (40 cycles) including denaturation at 95°C for
10 seconds, annealing at–60°C for 1 minute; melting curve
including denaturation at 95°C for 0 seconds, annealing at
65°C for 15 seconds, continuous melting at 95°C for 0 sec-
onds; cooling at 40°C for 30 seconds. All reactions were
performed in triplicate and included the following con-
trols: no template (RT NTC), no reverse transcriptase en-
zyme (no RT) and carrier MS2 RNA (carrier only). The
primers are listed in Table 4. The amplification was per-
formed in a Stratagene MX3005P in FrameStar 96 PCR
plates (BioLab Innovative Research Technologies, Poland).
Data analysis
Initial qPCR data analysis was performed using MXPro
software (Stratagene). Threshold cycle (Ct) for each miRNA
was extracted by setting a threshold and automatically
defined baseline. Furthermore, the data were analysed
statistically using Exiqon GenEx qPCR analysis software
(Exiqon, Denmark). miR-16-5p was used as a housekeep-
ing gene [42,43]. This miRNA is also a reference gene
found on Exiqon miRNome panels for plasma and is used
as a control for hemolysis. The fold change for each
miRNA was calculated using ΔΔCt method [45]. Data are
shown as means ± SEM.Additional file
Additional file 1: The expression of miR-21, miR-29, miR-30b,
miR-133b, miR-126, miR-423 and miR-125 in dogs with heart
failure divided into groups based on age (fold changes relative to
youngest group; mean ± SEM). Dogs were classified into three groups as
follow: group 1: 42.29 ± 21.91 months (mean ± SD, n = 7); group 2: 102.1 ±
14.57 months (mean ± SD, n = 8); gr 3: 157.6 ± 7.927 (mean ± SD, n = 8).Competing interests
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